Summary: In a post-hoc analysis of the MEAD trials, the dexamethasone intravitreal implant roughly doubled the likelihood of diabetic macular oedema resolution compared with sham, with a median time to first resolution of nine months, while higher baseline retinal thickness predicted slower resolution.
PICO Summary
| Element | Detail |
|---|---|
| Population | 701 eyes with diabetic macular oedema from the two phase 3 MEAD trials (351 dexamethasone, 350 sham), over 3 years. |
| Intervention | Dexamethasone 0.7 mg intravitreal implant, retreatment possible every ≥6 months. |
| Comparison | Sham procedure. |
| Outcome | Median time to first DME resolution (central thickness <250 µm) was 9.0 months with dexamethasone; hazard ratio for resolution versus sham 2.09 (p<0.0001). Higher baseline central retinal thickness was associated with longer time to resolution. (Raised intraocular pressure is a known effect of the implant from the parent trial.) |
Dexamethasone implant for DME resolution
MEAD post-hoc · type 2 diabetes · 3 years
The dexamethasone implant roughly doubled the rate of diabetic macular oedema resolution versus sham (HR 2.09), with a median time to first resolution of 9.0 versus 26.8 months. Higher baseline retinal thickness predicted slower resolution.
Expert Commentary
This is a sensible predictive sub-analysis of a landmark steroid-implant dataset, and its practical message is reasonable: the dexamethasone implant clearly speeds resolution of diabetic macular oedema relative to sham, and eyes with thicker maculae at baseline take longer to dry, which is intuitive given the greater fluid burden. For an ophthalmologist choosing and timing therapy, knowing that baseline thickness predicts a slower response is genuinely useful for setting expectations and retreatment planning. My caveats are mostly about framing for a general medical audience. This is a post-hoc analysis, so the predictor relationships are associations rather than prospectively validated rules, and the steroid implant carries the well-known trade-offs of raised intraocular pressure and cataract, which belong to the parent trial rather than being demonstrated anew here, so I have noted them as context rather than as a finding of this analysis. Can I use this with my patients? Only indirectly, since this is a specialist treatment decision. It does not change my management, but it reinforces the value of coordinating with ophthalmology and supporting the systemic foundations, glycaemic and blood-pressure control, that influence how diabetic macular oedema behaves and responds.
References
Valentim CCS, Lai H, Ogidigben MJ, Singh RP, Talcott KE. Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. BMC Ophthalmol. 2025;25(1):403. doi:10.1186/s12886-025-04208-3